Citations

Clear

3314 citation(s) found for "Do, Alexander".

Association of topoisomerase II expression and cancer-specific death in patients with surgically resected clear cell renal cell carcinoma.
Gardner, F., Serie, Daniel, Hilton, Tracy, Parasramka, Mansi, Eckel‐Passow, Jeanette E. , Cheville, John C. , Leibovich, Bradley C. , Parker, Alexander S. , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: e15539-e15539

10.1200/jco.2013.31.15_suppl.e15539 Get It

e15539 Background: Despite the development of prognostic algorithms based on clinico-pathologic features, the ability to identify aggressive forms of clear cell renal cell carcinoma (ccRCC) remains suboptimal. Topoisomerase IIA (TOP2a) is a biomarker of DNA replication and a target for antineoplastic agents. Herein, we evaluate the association of TOP2a expression in ccRCC tumors with pathologic features of aggressiveness and risk of cancer-specific death. Methods: We identified 1,380 patients who underwent nephrectomy to treat clinically localized ccRCC between 1/16/1990 and 4/14/2009. TOP2a expression was assessed using IHC and scored as number of positive cells per mm2. We evaluated TOP2a expression using a continuous variable and tertile categories. For associations with pathologic features we employed Kruskal-Wallis tests and for associations with cancer-specific survival we generated Cox proportional hazard regression models. Results: HigherTOP2a expression is associated with later stage, higher grade and higher MayoSSIGN score (all p < 0.001). The risk of death from RCC increases with increasing TOP2a expression (p trend < 0.0001), and this association remained strong after after multivariate adjustment for well-known predictors of RCC aggressiveness. Compared to patients in the lowest tertile, those patients with tumors in the highest tertile of TOP2a expression were at increased risk of RCC death (HR=2.62 95% CI 1.95-3.54; p<0.0001). Interestingly, among those patients with low risk disease (SSIGN score 0-3; ~95% 10 year survival), those with high TOP2a were at increased risk of RCC death (HR=3.48 95% CI 1.56-7.76; p =0.002). Conclusions: Higher TOP2a expression is associated with more aggressive pathologic features and increased risk of cancer-specific death among patients undergoing surgery for localized ccRCC. If confirmed, these data support further inquiry for TOP2a as a prognostic and predictive biomarker for ccRCC patients.
A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.
Gutierrez, Martin , Ansell, Stephen M. , Armand, Philippe , Borrello, Ivan , Segota, Zdenka E, Cattry, Deepika, Turner, Tracy, Mezes, M., Hartman, Christina, Gupta, Ashok , Wigginton, Jon M., Timmerman, John M. , Lesokhin, Alexander M. , Halwani, Ahmad , Cohen, Adam D. , Talpaz, Moshe , Hartman, Christina, Kim, Su Young

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: TPS3113-TPS3113

10.1200/jco.2013.31.15_suppl.tps3113 Get It

TPS3113 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that inhibits T-cell activation upon interaction with its ligands PD-L1 or PD-L2. Increased PD-L1 expression has been reported with various hematologic malignancies and may prevent the host immune response from exerting an antitumor effect on the malignant cells. Nivolumab, a fully human IgG4 monoclonal PD-1 receptor blocking antibody, has demonstrated antitumor activity in pts with solid tumors including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. We hypothesized that nivolumab could also mediate antitumor activity in pts with hematologic malignancies, a significant area of unmet medical need. We describe a phase I study to evaluate the effects of nivolumab in pts with select hematologic malignancies. Methods: This open-label, two-part study will enroll approximately 100 pts. During dose escalation, successive cohorts of pts with relapsed or refractory hematologic malignancies will be treated using a 6+3 escalation design. Pts will receive 1 or 3 mg/kg nivolumab IV every 2 weeks (wks) (the first dose will be followed by a 3-wk evaluation period), for 2 years, with the potential for an additional year of therapy for pts who progress during the follow-up period. Subsequently, 5 tumor-specific cohorts of 16 pts will be enrolled at the maximum tolerated dose (MTD) for multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma/primary mediastinal B-cell lymphoma, and chronic myelogenous leukemia. Response will be assessed at wks 4, 8, 16, 24, and every 16 wks thereafter. The primary study objective is to establish dose limiting toxicities, the MTD, and the recommended phase II nivolumab dose. Secondary objectives are to characterize nivolumab pharmacokinetics, immunogenicity, preliminary antitumor activity, and the potential association between PD-L1 expression on tumor cells and clinical efficacy. Exploratory objectives include investigation of the immunoregulatory effects of nivolumab in peripheral blood, bone marrow, and/or tumor. Pts are currently being enrolled at 3 mg/kg. Clinical trial information: NCT01592370.
Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study.
Hoffman‐Censits, Jean , Viterbo, Rosalia, Greenberg, Richard E. , Chen, David , Lallas, Costas D. , Wong, Yu‐Ning, Lin, Jianqing , Duncan, Gail, Adair, Beth, Cione, Charlotte, O'Sullivan, Conor, Kilpatrick, Deborah, Boorjian, Stephen A. , Kelly, William Kevin, Hudes, Gary R., Plimack, Elizabeth R. , Trabulsi, Edouard J. , Kutikov, Alexander , Ross, Eric A. , Uzzo, Robert G.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 4526-4526

10.1200/jco.2012.30.15_suppl.4526 Get It

4526 Background: Standard methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) demonstrates a survival benefit in the neoadjuvant setting for patients (pts) with muscle invasive bladder cancer (MIBC). Compared with standard MVAC, AMVAC yielded higher response rates with less toxicity in the metastatic setting. Methods: Pts with MIBC, cT2-T4a, and N0-N1 with CrCl >=50 and adequate hepatic and marrow function were eligible. Pts received 3 cycles of AMVAC (methotrexate 30 mg/m2, vinblastine 3 mg/m2, doxorubicin 30 mg/m2, cisplatin 70mg/m2) on day 1, with pegfilgrastim 6 mg day 2 or 3, every 2 weeks. Pts with CrCl < 60 could receive cisplatin split over 2 days. Radical cystectomy (RC) with lymph node dissection was performed 4-8 weeks after the last dose of chemotherapy. Primary endpoint was pathologic complete response (pCR) rate. Results: Accrual is complete with 44 MIBC pts enrolled at 2 institutions (FCCC, TJU) over a 25 month period. Median age 64 (range 45-83). Three withdrew from study early and are not evaluable for response (2 physician discretion, 1 withdrawal of consent). An additional 8 are currently receiving treatment on study with toxicity and response data pending. Of the 33 evaluable pts for whom final data is available, 30 received all 3 cycles of AMVAC at full dose. Three pts received < 3 cycles due to grade 3 fatigue (1), low platelets (1), and disease progression precluding RC (1). 32/33 pts underwent RC, all within 8 weeks of last chemotherapy. Median time from start of chemotherapy to RC was 9.7 wks (range 4.6-13 wks). 13/33 pts (39.4%, 95% CI, 22.7-56.1%) had a pCR. An additional 3 (9.1%) were downstaged to non muscle invasive disease. For the intent to treat cohort (n=36) 8 pts had grade 3-4 AMVAC related adverse events, the most common being anemia (3), fatigue (3) and neutropenia (2) and overall pCR rate was 36.1%. (95% CI, 20.4-51.8%). All pts will have completed study treatment by April 2012. Final results will be presented. Conclusions: Neoadjuvant AMVAC is well tolerated and preliminary results show a pCR rate similar to that reported for standard 12-week MVAC, suggesting that AMVAC for three cycles (6 weeks) is a safe and efficient alternative.
Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study
Erickson, Stephen B., Zand, Ladan , Nasr, Samih H. , Alexander, Mariam P., Drosou, Maria Eleni , Leung, Nelson , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | March 11, 2020 | Volume: 36 | Issue: 1 | Pages: 104-110

10.1093/ndt/gfaa065 | PMID 32617582 Get It

Abstract Background Fibrillary glomerulonephritis (FGN) is a rare type of glomerulonephritis with poor prognosis, with no known effective therapies available for treatment. The objective of the study was to evaluate the efficacy and safety of rituximab in treatment of patients with FGN and to investigate the effect of rituximab on DNAJB9 levels. Methods This was a pilot prospective clinical trial in which patients with idiopathic FGN were treated with two courses of rituximab (1 g each) 2 weeks apart at the beginning and then again at 6 months. Primary outcome was defined as preservation of kidney function at 12 months with stable or increased creatinine clearance. Secondary outcome was defined as achieving complete remission (CR) defined as proteinuria &lt;300 mg/24 h or partial remission (PR) with proteinuria &lt;3 g/24 h and at least 50% reduction in the proteinuria. DNAJB9 levels were also measured in the serum at baseline, 6 and 12 months. Results The creatinine clearance did not change significantly during this time, from 47.7 mL/min/1.73 m2 at baseline to 43.7 mL/min/1.73 m2 during follow-up (P = 0.15). Proteinuria declined from 4.43 (1.6–5.53) g/24 h at baseline to 1.9 (0.46–5.26) g/24 h at 12 months but did not reach significance (P = 0.06). None of the patients reached CR, and 3 of the 11 achieved PR. There was no change in the DNAJB9 levels following treatment with rituximab. The most common adverse event was nasal congestion, fatigue and muscle cramps. Conclusions Treatment of patients with two courses of rituximab over a span of 6 months was associated with stabilization of renal function but did not result in a significant change in proteinuria and with no change in the DNAJB9 levels.
The role of integrins in melanoma: a review
Arias‐Mejias, Suzette M. , Warda, Katerina Y., Quattrocchi, Enrica , Alonso‐Quinones, Hector, Sominidi‐Damodaran, Sindhuja , Meves, Alexander , Alonso-Quinones, Hector J.

Mayo Clinic

International Journal of Dermatology | March 11, 2020 | Volume: 59 | Issue: 5 | Pages: 525-534

10.1111/ijd.14850 | PMID 32157692 Get It

Abstract Integrins are the major family of cell adhesion receptors in humans and essential for a wide range of normal physiology, including formation and maintenance of tissue structure integrity, cell migration, proliferation, and differentiation. Integrins also play a prominent role in tumor growth and metastasis. Translational research has tried to define the contribution of integrins to the phenotypic aggressiveness of melanoma because such knowledge is clinically useful. For example, differential expression of integrins in primary cutaneous melanoma can be used to distinguish indolent from aggressive, prometastatic melanoma. Recent studies have shown that gene expression–based testing of patient‐derived melanoma tissue is feasible, and molecular tests may fully replace interventional surgical methods such as sentinel lymph node biopsies in the future. Because of their central role in mediating invasion and metastasis, integrins are likely to be useful biomarkers. Integrins are also attractive candidate targets for interventional therapy. This article focuses on the role of integrins in melanoma and highlights recent advances in the field of translational research.
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
Schuetze, Scott M. , Tine, Brian Andrew Van, Attia, Steven , Hu, James , Okuno, Scott H. , Priebat, Dennis A., Movva, Sujana , Keung, Emily Z. , Baker, Laurence H. , Patel, Shreyaskumar , Tawbi, Hussein, Burgess, Melissa , Bolejack, Vanessa , Riedel, Richard F. , Davis, Lara E. , Reed, Damon R. , D'Angelo, Sandra P , Lazar, Alexander J. , Reinke, Denise K. , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11015-11015

10.1200/jco.2019.37.15_suppl.11015 Get It

11015 Background: Immune checkpoint inhibitors have demonstrated activity in multiple tumor types but their activity in soft tissue sarcomas remains limited. In the multicenter phase II study, SARC028, the anti-PD-1 antibody, P demonstrated objective responses that were largely restricted to UPS and LPS subtypes. We now report outcomes from 2 expansion cohorts of SARC 028 in advanced UPS and LPS. Methods: To further confirm the clinical activity of P in UPS and LPS, we enrolled an additional 30 pts in each of 2 expansion cohorts for a total of 40 UPS and 40 LPS pts. Primary endpoint was investigator-assessed response by RECIST v1.1. Secondary endpoints were safety, progression-free survival (PFS), 12-week PFS rate, and overall survival (OS). An ORR of 25% was considered clinically meaningful and < 10% was considered to show lack of efficacy. P was to be considered a success if 8 or more of 40 enrolled patients had a PR or better (1-sided α = 0.042, 82% power). Pts age ≥18 with advanced, refractory UPS or LPS received 200 mg of P IV every 3 weeks until progression or unacceptable toxicity. Results: Preliminary results from the first 10 pts in each of the UPS and LPS cohorts have been reported. We now present summary data after enrolling an additional 30 pts in each cohort. The ORR in the UPS cohort was 23% (9/40), with an additional 5/30 PRs observed in the expansion cohort (total 2 CRs, 7 PRs). In the LPS cohort, the ORR was 10% (4/39 evaluable pts), with an additional 2/30 PRs observed (total 4 PRs). Median PFS for the UPS group was 3 months [95% CI: 2, 5] and 2 months [95% CI: 2, 4] for the LPS group. 12-week PFS rate was 50% in UPS [95% CI: 35, 65] and 44% in LPS [95% CI: 28, 60]. The UPS group had a median OS of 12 months [95% CI: 7, 34] and 13 months [95% CI: 8, NR] for the LPS group. P was well tolerated with no unexpected toxicities. Conclusions: The UPS cohort achieved its primary endpoint, however the activity of P in UPS deserves further evaluation in a randomized study. The activity of P was not confirmed in the LPS cohort. Ongoing biomarker analyses may direct better patient selection and guide future combination strategies. Clinical trial information: NCT02301039.
Predictors of Nonconvulsive Seizure and Their Effect on Short-term Outcome
Singh, Jaysingh , Rayi, Appaji , Peng, Juan , Bell, W., Britton, Jeffrey, Thakur, Gaurav , Alexander, J. Steven , Bell, William, Britton, Jeffrey W.

Mayo Clinic

Journal of Clinical Neurophysiology | March 6, 2020 | Volume: 38 | Issue: 3 | Pages: 221-225

10.1097/wnp.0000000000000687 | PMID 32141985 Get It

Introduction: Nonconvulsive seizures (NCSs) are common in critically ill adult patients with acute neurologic conditions. However, the effect of NCSs on patient outcome remains unclear. In this study, we aimed to determine the effect of NCSs on short-term outcome and to assess the clinical and EEG factors associated with NCSs. Methods: We retrospectively identified 219 adult patients from the EEG reporting system who underwent continuous EEG (cEEG) monitoring between January 2018 and June 2018. Patients with anoxic brain injury were excluded from the study. Clinical, laboratory, and EEG data were reviewed to determine potentially predictive factors of NCSs. The impact of NCSs on in-hospital mortality, length of stay, and disability on discharge was measured; an modified Rankin scale of three or greater was considered disabled. Results: Of the 219 patients included in our study, a total of 14% (n = 31) had NCSs on continuous EEG, of which 42% (n = 13) had their first seizure discharge recorded during the first hour of continuous EEG monitoring. The presence of clinical seizures before continuous EEG (odds ratio = 1.787; 95% confidence interval = 1.197–2.667, P = 0.0045), history of epilepsy (odds ratio = 1.508; 95% confidence interval = 1.027–2.215, P = 0.035), and comatose state (29 vs. 16%; P = 0.0006) were associated with NCSs. Among EEG characteristics, the presence of interictal epileptiform discharges (P < 0.0001), lateralized rhythmic delta activity (P = 0.02), and lateralized periodic discharges (P < 0.0001) were associated with NCSs. Nonconvulsive seizures were significantly associated with longer in-hospital stay (23.68 ± 24.84 vs. 17.14 ± 20.52; P = 0.036) and disability on discharge (87% [n = 27] vs. 13% [n = 4], P = 0.02). However, there was no significant association between NCS and in-hospital mortality (9.6% [n = 3] vs. 10.6% [n = 20]; P = 0.1). Conclusions: Nonconvulsive seizures are associated with longer in-hospital stay and disability on discharge but not with in-hospital mortality in adult patients.
Inhibition of stearoyl‐CoA desaturases suppresses follicular help T‐ and germinal center B‐ cell responses
Son, Young Min , Cheon, In Su , Goplen, Nick P., Dent, Alexander L. , Sun, Jie , Sun, Jie , Dent, Alexander L

Mayo Clinic

European Journal of Immunology | March 4, 2020 | Volume: 50 | Issue: 7 | Pages: 1067-1077

10.1002/eji.201948257 | PMID 32133634 Get It

Abstract Stearoyl‐CoA desaturases (SCD) are endoplasmic reticulum (ER)‐associated enzymes that catalyze the synthesis of the monounsaturated fatty acids (MUFAs). As such, SCD play important roles in maintaining the intracellular balance between saturated fatty acid (SFAs) and MUFAs. The roles of SCD in CD4 + T‐helper cell responses are currently unexplored. Here, we have found that murine and human follicular helper T (T FH ) cells express higher levels of SCD compared to non‐T FH cells. Further, the expression of SCD in T FH cells is dependent on the T FH lineage‐specification transcription factor BCL6. We found that the inhibition of SCD impaired T FH cell maintenance and shifted the balance between T FH and follicular regulatory T (T FR ) cells in the spleen. Consequently, SCD inhibition dampened germinal center B‐cell responses following influenza immunization. Mechanistically, we found that SCD inhibition led to increased ER stress and enhanced T FH cell apoptosis in vitro and in vivo. These results reveal a possible link between fatty acid metabolism and cellular and humoral responses induced by immunization or potentially, autoimmunity.
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
González-Ericsson, Paula I. , Stovgaard, Elisabeth Specht , Reisenbichler, Emily , Kos, Zuzana , Carter, Jodi M. , Michiels, Stefan , Quesne, John Le , Lænkholm, Anne‐Vibeke , Adam, Julien , Bartlett, John MS, Rimm, David L. , Quinn, Cecily , Cree, Ian A. , Hida, Akira I. , Haynes, Harry R. , Frahm, Isabel, Acosta‐Haab, Gabriela, Balancin, Marcelo Luiz , Bellolio, Enrique , Yang, Wentao , Kirtani, Pawan , Sugie, Tomoharu , Ehinger, Anna , Castaneda, Carlos, Kok, Marleen , McArthur, Heather L. , Siziopikou, Kalliopi P. , Fineberg, Susan , Gown, Allen M. , Viale, Giuseppe , Schnitt, Stuart J. , Pruneri, Giancarlo , Penault‐Llorca, Frederique, Hewitt, Stephen M. , Thompson, E. Aubrey , Allison, Kimberly H. , Symmans, W. Fraser , Bellizzi, Andrew M. , Brogi, Edi , Moore, David A. , Larsimont, Denis , Dillon, Deborah , Broeckx, Glenn , Bairi, Khalid El , Cimino‐Mathews, Ashley , Adams, Sylvia , Liu, S, Loibl, Sibylle , Chen, I‐Chun , Juco, Jonathan, Blackley, Elizabeth F. , Demaria, Sandra , Leon‐Ferre, Roberto A. , Zardavas, Dimitrios, Emancipator, Kenneth , Ely, Scott , Loi, Sherene , Salgado, Roberto , Group, International Immuno‐Oncology Biomarker Working, Cree, Ian , Haynes, Harry R , Balancin, Marcelo , Ehinger, Anna , Lazar, Alexander J , Broeckx, Glenn , El Bairi, Khalid , Leon-Ferre, Roberto, Gonzalez-Ericsson, Paula I , Bellizzi, Andrew M , Symmans, W Fraser , Loi, Sherene , Pruneri, Giancarlo , Rimm, David , Carter, Jodi , Sua, Luz Fernanda , Nielsen, Torsten O. , Fox, Stephen B. , Bartlett, John MS, Peeters, Dieter J. E. , Dieci, Maria Vittoria , Vincent‐Salomon, Anne , Balko, Justin M. , Badve, Sunil , Penault-Llorca, Frederique Madeleine , Lazar, Alexander J. , Lien, Huang‐Chun , Goetz, Matthew P. , Harbeck, Nadia , Sotiriou, Christos P. , Lakhani, Sunil R. , Denkert, Carsten , Gluz, Oleg , Sanders, Melinda E. , Group, International Immuno‐Oncology Biomarker Working

Mayo Clinic

The Journal of Pathology | March 4, 2020 | Volume: 250 | Issue: 5 | Pages: 667-684

10.1002/path.5406 | PMID 32129476 Get It

AbstractImmune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Absent, Abnormal, or Reduced Flow in the Testis: Thinking Beyond Torsion
Alexander, Lauren F. , Caserta, Melanie P. , Baden, Kerri , Livingston, David H. , Cernigliaro, Joseph G. , Bhatt, Shweta , Livingston, David , Alexander, Lauren F , Bhatt, Shweta

Mayo Clinic

RadioGraphics | March 3, 2020 | Volume: 40 | Issue: 2 | Pages: 529-530

10.1148/rg.2020190111 | PMID 32125958 Get It